Speech perception

Widex MOMENT Wins 2023 HearAdvisor Expert Choice Award

Retrieved on: 
Thursday, July 27, 2023

HAUPPAUGE, N.Y., July 27, 2023 /PRNewswire/ -- Widex USA Inc. today announced that its Widex Moment hearing aids have been recognized as a winner in the first-ever HearAdvisor Expert Choice Awards. Widex Moment™ was one of only 11 winners out of 46 evaluated hearing devices.

Key Points: 
  • HAUPPAUGE, N.Y., July 27, 2023 /PRNewswire/ -- Widex USA Inc. today announced that its Widex Moment hearing aids have been recognized as a winner in the first-ever HearAdvisor Expert Choice Awards.
  • "Until the launch of Widex Moment, hearing aids have always sounded like hearing aids," stated Dana Helmink, Senior Director of Audiology and Clinical Education at Widex USA.
  • We are proud to join the exclusive circle of manufacturers to have won a HearAdvisor Expert Choice Award."
  • This honor is the latest in a growing list of award wins for Widex Moment and its compatible technologies.

Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Friday, March 10, 2023

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2022.

Key Points: 
  • Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2022.
  • MS in characterized by demyelination, stripping axons of the myelin sheaths that support neuronal signal conduction and axonal survival.
  • Net Loss: Net loss was $17.4 million for the three months ended December 31, 2022, as compared to $21.5 million for the comparable period of 2021.
  • Net loss was $81.6 million for the full year ended December 31, 2022, as compared to $84.7 million for the comparable period of 2021.

Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss

Retrieved on: 
Monday, February 13, 2023

The study, which enrolled 142 people with either sudden or noise-induced sensorineural hearing loss, failed to achieve its primary efficacy endpoint of an improvement in speech perception.

Key Points: 
  • The study, which enrolled 142 people with either sudden or noise-induced sensorineural hearing loss, failed to achieve its primary efficacy endpoint of an improvement in speech perception.
  • Prior FX-322 studies had been designed to best understand patient etiologies and severities where a hearing signal could be observed.
  • The safety profile associated with FX-322 was favorable and no study participants experienced a serious adverse event that was associated with treatment.
  • Given these disappointing results, we will cease further development of the Company's drug candidates for hearing loss.

Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company’s Second Therapeutic Candidate for Sensorineural Hearing Loss

Retrieved on: 
Thursday, December 15, 2022

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a persons innate potential to restore function, today announced that it has dosed a first patient in the Phase 1b study of FX-345, the Companys second hearing restoration candidate for sensorineural hearing loss (SNHL).

Key Points: 
  • Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a persons innate potential to restore function, today announced that it has dosed a first patient in the Phase 1b study of FX-345, the Companys second hearing restoration candidate for sensorineural hearing loss (SNHL).
  • Advancing FX-345 to the clinic is an exciting milestone as we further our pioneering work to develop regenerative therapeutics for hearing loss.
  • Frequency is also evaluating FX-322, a therapeutic candidate for SNHL, in an ongoing Phase 2b study (FX-322-208).
  • Sensorineural hearing loss is the most common form of hearing loss, typically resulting from damage to sensory hair cells in the cochlea.

Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results

Retrieved on: 
Thursday, November 17, 2022

A Phase 2b study of FX-322 (FX-322-208) is fully enrolled with clinical results anticipated in the first quarter of 2023.

Key Points: 
  • A Phase 2b study of FX-322 (FX-322-208) is fully enrolled with clinical results anticipated in the first quarter of 2023.
  • They will also discuss how a medicine for cochlear regeneration may fit with currently available hearing devices and the clinical significance of speech perception on overall hearing.
  • Kevin Franck, Ph.D., SVP, Strategic Marketing and New Product Planning: Cochlear restoration market development and the demand for new therapeutics.
  • Carl LeBel, Ph.D., Chief Development Officer: FX-322 hearing restoration program and the clinical development path.

Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results

Retrieved on: 
Tuesday, November 8, 2022

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a persons innate potential to restore function, today announced business updates and financial results for the third quarter ended September 30, 2022.

Key Points: 
  • Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a persons innate potential to restore function, today announced business updates and financial results for the third quarter ended September 30, 2022.
  • FX-322-208 Phase 2b Study in Acquired Sensorineural Hearing Loss (SNHL): In October, Frequency announced enrollment completion for its FX-322-208 study.
  • FX-322-208 is a randomized, placebo-controlled, multi-center study designed to evaluate the efficacy of a single administration of FX-322 on speech perception.
  • Pre-clinical Program for Remyelination in Multiple Sclerosis (MS): Frequency is advancing to IND-enabling studies its program for remyelination in MS.

Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss

Retrieved on: 
Wednesday, October 12, 2022

I am very pleased with our teams execution of this study for the first potential treatment to restore hearing for those with SNHL.

Key Points: 
  • I am very pleased with our teams execution of this study for the first potential treatment to restore hearing for those with SNHL.
  • We believe the high level of interest from patients and healthcare providers in this study further demonstrates the need for a novel, disease modifying hearing loss treatment to expand the standard of care for the millions of individuals with sensorineural hearing loss.
  • With improved speech perception, individuals may hear words more clearly, a critical unmet need for individuals with hearing loss.
  • Sensorineural hearing loss is the most common form of hearing loss, typically resulting from damage to sensory hair cells in the cochlea.

Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results

Retrieved on: 
Tuesday, August 9, 2022

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a persons innate potential to restore function, today announced business updates and financial results for the second quarter ended June 30, 2022.

Key Points: 
  • Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a persons innate potential to restore function, today announced business updates and financial results for the second quarter ended June 30, 2022.
  • Across the enterprise, we continue to carefully manage expenses and have cash sufficient to move our programs through important data events and milestones.
  • FX-345, a Second Program for SNHL: FX-345 is the Companys second investigational therapeutic candidate for SNHL.
  • Cash Position: Cash, cash equivalents and marketable securities as of June 30, 2022, were $111.0 million (excluding restricted cash).

Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results

Retrieved on: 
Wednesday, May 4, 2022

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a persons innate regenerative potential to restore function, today announced business updates and financial results for the first quarter ended March 31, 2022.

Key Points: 
  • Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a persons innate regenerative potential to restore function, today announced business updates and financial results for the first quarter ended March 31, 2022.
  • Frequency continues to make important progress executing our pipeline of therapeutic programs for hearing loss and remyelination in multiple sclerosis (MS).
  • FX-345 is being evaluated in IND-enabling studies and Frequency anticipates filing an IND application for FX-345 in the second half of 2022.
  • Cash Position: Cash, cash equivalents and marketable securities as of March 31, 2022, were $124.8 million (excluding restricted cash).

ENTA Conducting Clinical Trial of Investigational Regenerative Medication to Restore Hearing Function in Sensorineural Hearing Loss (SNHL) Patients

Retrieved on: 
Friday, March 11, 2022

Frequency Therapeutics, Inc. is a clinical-stage regenerative medicine company focused on developing therapeutics to activate a persons innate regenerative potential to restore function.

Key Points: 
  • Frequency Therapeutics, Inc. is a clinical-stage regenerative medicine company focused on developing therapeutics to activate a persons innate regenerative potential to restore function.
  • Sensorineural Hearing Loss (SNHL) is the most prevalent form of hearing loss and is typically acquired through excessive noise exposure or loud sounds over extended periods of time.
  • Dr. Chandrasekhar says, We know that regenerative medicine holds limitless potential usesand restoring speech perception in patients with sensorineural hearing loss is one of the most important uses I can think of.
  • Frequency is also following early restorative signals in MS to develop medicines with the same underlying regenerative science being brought to hearing loss.